Halozyme Therapeutics Inc. Stock
A very strong showing by Halozyme Therapeutics Inc. today, with an increase of €14.44 (19.390%) compared to yesterday's price.
The stock is one of the favorites of our community with 24 Buy predictions and 1 Sell predictions.
As a result the target price of 91 € shows a slightly positive potential of 2.04% compared to the current price of 89.18 € for Halozyme Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Halozyme Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 19.390% | 24.588% | 24.832% | 67.317% | 52.184% | 131.336% | 159.094% |
| Ligand Pharmaceuticals | -3.820% | -0.781% | -9.286% | 117.094% | 53.012% | 319.835% | 171.194% |
| United Therapeutics | -0.580% | 3.809% | -5.572% | 81.464% | 9.057% | 115.541% | 156.044% |
| Ionis Pharmaceuticals Inc. | 1.990% | 8.773% | -35.384% | 39.931% | -28.119% | 37.451% | 47.985% |
Comments
Halozyme Therapeutics (HALO) had its price target raised by TD Cowen from $96.00 to $105.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its price target raised by HC Wainwright from $95.00 to $115.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (HALO) had its "buy" rating reaffirmed by Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
News
Halozyme Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Halozyme Therapeutics, Inc.? Here are five stocks we like better.
- Record Q2 performance: Revenue rose 48% year over year to $481 million, while royalty revenue increased
LifeMD Q2 Earnings Call Highlights
Key Points
- Interested in LifeMD, Inc.? Here are five stocks we like better.
- Q2 profitability missed expectations: LifeMD reported $47.3 million in revenue and an adjusted EBITDA loss of about
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
Key Points
- Interested in argenex SE? Here are five stocks we like better.
- argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise